Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol
This article was originally published in The Pink Sheet Daily
Executive Summary
It’s been a long haul, but Sanofi’s Genzyme business unit and Isis have submitted their NDA for a drug that helps lower cholesterol levels in high-risk patients with a rare genetic cardiovascular disease that doesn’t respond well to statins.
You may also be interested in...
Dearth Of Clinical Data For Aegerion’s Lomitapide May Sidetrack Advisory Committee Review
Aegerion submitted the lomitapide NDA Feb. 29 with 54-week data from a single-arm, open-label trial, hoping for priority review based on the lack of effective treatments for homozygous familial hypercholesterolemia. Meanwhile, Isis/Sanofi submitted their competing candidate mipomersen March 29 with two-year extension-study data.
Isis Books Kynamro Milestone; Seeks Partners For Other Pipeline Assets
The focus at Isis turns to the near-term prospects of an approval for the cholesterol drug Kynamro and to business development.
Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder
The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.